Author + information
- Received April 25, 2017
- Revision received June 16, 2017
- Accepted July 19, 2017
- Published online October 2, 2017.
- Mohamad Alkhouli, MDa,b,
- Charanjit S. Rihal, MDa,∗ (, )
- Chad J. Zack, MDa,
- Mackram F. Eleid, MDa,
- Elad Maor, MD, PhDa,
- Mohammad Sarraf, MDa,
- Allison K. Cabalka, MDc,
- Guy S. Reeder, MDa,
- Donald J. Hagler, MDa,c,
- Joseph F. Maalouf, MDa,
- Vuyisile T. Nkomo, MD, MPHa,
- Hartzell V. Schaff, MDd and
- Sameh M. Said, MDd
- aDepartment of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota
- bDivision of Cardiovascular Diseases, West Virginia University, Morgantown, West Virginia
- cDivision of Pediatric Cardiology, Mayo Clinic College of Medicine, Rochester, Minnesota
- dDepartment of Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota
- ↵∗Address for correspondence:
Dr. Charanjit S. Rihal, Mayo Clinic, Department of Cardiovascular Medicine, 200 First Street, Rochester, Minnesota 55901.
Objectives The aim of this study was to report the use trends and immediate and long-term outcomes of a large cohort of patients who underwent redo surgery or transcatheter repair of paravalvular leaks (PVLs) at a tertiary referral center.
Background Percutaneous treatment of mitral PVL has emerged as an alternative to surgical treatment in high-risk surgical candidates. There are limited data on the utilization trends, safety, and efficacy of both procedures in the management of mitral PVL.
Methods Patients who underwent treatment of mitral PVL at the Mayo Clinic between January 1995 and December 2015 were enrolled. Utilization trends, procedural details, technical success, and in-hospital and long-term outcomes were assessed.
Results Three hundred eighty-one patients underwent percutaneous (n = 195) or surgical (n = 186) treatment of mitral PVLs. The mean age was 66 ± 12 years, and 37% of patients had bioprosthetic valves. Technical success was higher in the surgical group (95.5% vs. 70.1%; p < 0.001). In-hospital major adverse events were more common after surgery (22.5% vs. 7.7%; p < 0.001). In-hospital death occurred in 3.1% and 8.6% of patients undergoing percutaneous and surgical treatment, respectively (p = 0.027). However, in a multivariate logistic regression analysis, only active endocarditis, chronic renal failure, and severe mitral annular calcifications were significant predictors of in-hospital mortality. Reintervention rates were similar (11.3% vs. 17.2% in the percutaneous and surgical groups, respectively; p = 0.10), with the majority of reinterventions in the percutaneous group occurring early because of residual leak or persistent hemolysis. After risk adjustment, there was no significant difference in long-term survival between patients who underwent surgical versus transcatheter treatment of PVLs.
Conclusions In contemporary practice, patients with symptomatic mitral PVLs are best treated with an integrated team approach incorporating both surgical and percutaneous techniques. Patient selection and timing of intervention are critical to achieve optimal results.
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received April 25, 2017.
- Revision received June 16, 2017.
- Accepted July 19, 2017.
- 2017 American College of Cardiology Foundation